Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor

Cancer Gene Therapy

Volumn 9, Issue 9, 2002, Pages 778-786

  Chen, Zhuang ^a   Huang, Hui ^a   Chang, Tim ^a   Carlsen, Svein ^a   Saxena, Anurag ^a   Marr, Robert ^b   Xing, Zhou ^b   Xiang, Jim ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Alpha necrosis factor; Antitumor immunity; Engineered dendritic cell vaccine; HER 2; Recombinant adenovirus

Indexed keywords

CD40 ANTIGEN; CD86 ANTIGEN; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENE PRODUCT; IMMUNOLOGICAL ADJUVANT; INTERCELLULAR ADHESION MOLECULE 1; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CANCER VACCINE; PRIMER DNA;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ENGINEERING; IMMUNE RESPONSE; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; VACCINATION; WESTERN BLOTTING; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMISTRY; COMPARATIVE STUDY; CYTOTOXICITY TEST; EXPERIMENTAL NEOPLASM; FEMALE; GENE VECTOR; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; LACTOSE OPERON; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

ADENOVIRIDAE; ANIMAL; BLOTTING, WESTERN; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMPARATIVE STUDY; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; DNA PRIMERS; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; INTERCELLULAR ADHESION MOLECULE-1; LAC OPERON; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPPORT, NON-U.S. GOV'T; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR NECROSIS FACTOR; ANIMALS; TUMOR NECROSIS FACTOR-ALPHA;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 0036708237     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700498     Document Type: Article

References (42)

1. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
2. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
3. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells
4. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer
5. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
6. T cell recognition of human tumors: Implications for molecular immunotherapy of cancer
7. High titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
8. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
9. + tumors
10. Peptides derived from a wild-type murine protooncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts
11. Monoclonal antibody therapy of cancer
12. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors
13. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA
14. Vaccination with HER-2/neu DNA or protein subunits protects against growth of a HER-2/neu-expressing murine tumor
15. Decreased antigen presentation by dendritic cells in patients with breast cancer
16. Minimal recruitment and activation of dendritic cells within renal cell carcinoma
17. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats
18. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells
19. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
20. Origin, maturation and antigen presenting function of dendritic cells
21. Cancer vaccines
22. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration
23. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells
24. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus
25. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100
26. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
27. TNF-transgene-expressing dendritic cells undergo augmented cellular maturation and induce more robust T cell activation and antitumor immunity than dendritic cells generated in recombinant TNF
28. Adenovirus-mediated TNF-α gene transfer induces significant tumor regression in mice
29. Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1
30. Direct activation of CD8 cytotoxic T lymphocytes by dendritic cells
31. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis
32. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α
33. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12
34. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity
35. Induction of ErbB-2/neuspecific protective and therapeutic antitumor immunity using genetically modified dendritic cells: Enhanced efficacy by cotransduction of gene encoding IL-12
36. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant
37. Dendritic cells and the control of immunity
38. Cytokines and their effects on maturation, differentiation and migration of dendritic cells
39. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic antitumor immune responses in vivo
40. Tumor necrosis factor-α is required for accumulation of dendritic cells in draining lymph nodes and for optimal contact sensitization
41. Defining promiscuous MHC class II helper T-cell epitopes for the HER-2/neu tumor antigen
42. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway